CV Sciences (CVSI) Income from Continuing Operations (2011 - 2026)
CV Sciences (CVSI) posted Income from Continuing Operations of 643000.0 for Q1 2026, down 499.38% sequentially from 161000.0 in Q4 2025, and down 489.91% YoY from 164910.59 in Q1 2025.
CV Sciences (CVSI) Income from Continuing Operations (2011 - 2026) Analysis & Trends
CV Sciences has reported Income from Continuing Operations for 16 years, with the latest figure at 643000.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 489.91% year-over-year to 643000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 1125000.0 (up 30.3% YoY) and the FY2025 annual result came in at 591000.0, up 72.29% from the prior year.
- Income from Continuing Operations eased to 643000.0 in Q1 2026 per CVSI's latest filing, from 161000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 5706000.0 in Q1 2023 and troughed at 2653000.0 in Q2 2022.
- A 5-year average of 394294.12 and a median of 584000.0 in 2024 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2022 and 2023: Income from Continuing Operations tumbled 2477.5% in 2022, then soared 369.79% in 2023.
- Over 5 years, Income from Continuing Operations stood at 625000.0 in 2022, then plunged by 41.28% to 883000.0 in 2023, then jumped by 47.34% to 465000.0 in 2024, then surged by 134.62% to 161000.0 in 2025, then plunged by 499.38% to 643000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 643000.0, 161000.0, and 382000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 1.33 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | CV Sciences | 4.10 Mn | 3.84 Mn | 1.45 Mn | -775,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -775,000.00 |
| Mar 31, 2026 | -643,000.00 |
| Dec 31, 2025 | 161,000.00 |
| Sep 30, 2025 | -382,000.00 |
| Jun 30, 2025 | -261,000.00 |
| Mar 31, 2025 | -109,000.00 |
| Dec 31, 2024 | -465,000.00 |
| Sep 30, 2024 | -456,000.00 |
| Jun 30, 2024 | -584,000.00 |
| Mar 31, 2024 | -628,000.00 |
| Dec 31, 2023 | -883,000.00 |
| Sep 30, 2023 | -447,000.00 |
| Jun 30, 2023 | -1.29 Mn |
| Mar 31, 2023 | 5.71 Mn |
| Dec 31, 2022 | -625,000.00 |
| Sep 30, 2022 | -1.03 Mn |
| Jun 30, 2022 | -2.65 Mn |
| Mar 31, 2022 | -2.12 Mn |
| Dec 31, 2021 | -8.86 Mn |
| Sep 30, 2021 | -40,000.00 |